Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2. - Wikidata - thesis-toulmin - TriplyDB

Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.

Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.

http://www.wikidata.org/entity/Q33242744

about

Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma Clinical utility of ramucirumab in advanced gastric cancer Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers Evolution of ramucirumab in the treatment of cancer - A review of literature Antivascular therapy for epithelial ovarian cancer.The VEGF family in cancer and antibody-based strategies for their inhibition.Targeted inhibition of VEGF receptor 2: an update on ramucirumab.Ramucirumab: preclinical research and clinical development.Clinical advances in the development of novel VEGFR2 inhibitors.Anti-angiogenic therapies for advanced esophago-gastric cancer Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo.IgG Fab fragments forming bivalent complexes by a conformational mechanism that is reversible by osmolytes.Prostaglandin E2 and vascular endothelial growth factor A mediate angiogenesis of human ovarian follicular endothelial cells.Vascular endothelial growth factor: biology and therapeutic applications.Vascular endothelial growth factor in eye disease.Ramucirumab for the treatment of gastroesophageal cancers.State of the art in anti-cancer mAbs.Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.Neovascular age-related macular degeneration: opportunities for development of first-in-class biopharmaceuticals.Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.An active murine-human chimeric Fab antibody derived from Escherichia coli, potential therapy against over-expressing VEGFR2 solid tumors.Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma.Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.Ramucirumab: A Review in Advanced Gastric Cancer.The Impact of Ramucirumab on Survival in Patients with Advanced Solid Tumors: A Systematic Review and Meta-Analysis of Randomized II/III Controlled Trials.Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives.Current status of ramucirumab in gastroesophageal adenocarcinoma.Ramucirumab Clinical Development: an Emerging Role in Gastrointestinal Tumors.Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer.The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine.Identification and in vitro characterization of phage-displayed VHHs targeting VEGF.Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity.Feed-forward signaling by membrane-bound ligand receptor circuit: the case of NOTCH DELTA-like 4 ligand in endothelial cells.Phage display-derived human antibodies in clinical development and therapy Generation and characterization of a novel human IgG1 antibody against vascular endothelial growth factor receptor 2.

P2860

Q26750715-E984B116-E10B-4312-BCDD-82A56336FE6F Q26776198-B15F94CF-C076-4294-AE2B-5225B5B89527 Q26777690-525A1BF7-5CF3-486B-936B-58E148035AE5 Q26785665-691F7F22-31CE-4B90-9218-D3037A28B952 Q26801289-83474BDA-8C57-4AD3-AF6C-720D1F67571B Q28276412-711096F0-B580-4F1C-B015-AB80CC45A105 Q33583598-0209E557-6134-4EB7-9B38-95729779AFC2 Q33733437-980F0080-FFF1-4A27-A9FF-C7CEABCDF614 Q34040956-C4704B36-7DD9-4B73-AA52-D050556AB0D8 Q34446310-82F22019-7253-4695-A36B-F5259F6DE4D9 Q34658366-D6D8CBE4-45B9-44C1-9375-E7183DEF377E Q34686222-B77B4096-1D3D-4B1E-BEE4-03149487F462 Q34947216-D4D0C0EB-A267-4980-A077-8D52C3FA0CD4 Q36466773-D6E2E8E6-F5A5-4F4B-A1EC-E80350BDB84C Q36473768-D3D47B4F-F2A7-4A85-B36F-850DE6F877E4 Q36835234-D8CF32AB-D49F-4656-83EB-137EA03AC97C Q36929380-5AFD26A8-541A-477D-82F0-88379EDD35A2 Q37211153-121A8C7D-9D11-4421-A35A-B8F5A6E2E157 Q37655585-F53F4390-7564-43DE-A8E0-48E4D62B76E6 Q37706985-858C93E5-1FD7-446E-88A2-BD29A9AE6121 Q37882685-B81B2B5C-975B-45EE-A210-4709EB4AFFCF Q38166329-C8BBD850-F9FE-4743-883F-90C94AE53576 Q38286373-86E61285-C820-47DB-A19F-E7DE35461CEB Q38410220-112C8FC4-0030-4C46-9547-EF89081B90BC Q38513056-4779792C-7311-4940-812B-1117798C098B Q38578404-AC582AF4-9B01-4560-8E16-5B70D3666EA4 Q38581171-E29A8D36-7047-4F03-8444-14C01DBC9304 Q38627686-D34F6AAD-4F40-4979-A58F-2748867038FD Q38632917-7483D07D-EC3E-4645-AE90-B62904C425CA Q38691733-E7D1B4B9-9139-4F66-BB75-BBC8B13BCECD Q38737639-1DA769CD-607E-4C0B-8E63-867BCF4B1E8C Q38741222-8B8FFFFB-FBD6-442F-AD4B-569007EA622D Q38825283-CDAAC2E6-A841-4BF9-87C2-6B2DE60493FA Q38826507-34F808F1-2A8B-47E1-ADFF-AA9B34116137 Q38829551-1AC65407-E490-4454-8F02-952261EDD305 Q39051064-77AB19AA-C9DE-461F-BE54-7B3AB1F6636A Q39458295-56960871-6CA3-4C99-A635-62525BD8B70A Q41197641-93D89B76-56E7-488D-87F1-883B5EA2CA04 Q41416393-C88417EA-0200-4F72-954A-0DEBFCA771A7 Q42801724-CCB7B0C5-BBC7-4D0E-B14F-E5F8E40FA944

P2860

Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.

http://www.wikidata.org/entity/Q33242744

description

2006 nî lūn-bûn

@nan

2006 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Potent neutralization of VEGF ...... ected against VEGF receptor 2.

@ast

Potent neutralization of VEGF ...... ected against VEGF receptor 2.

@en

type

label

Potent neutralization of VEGF ...... ected against VEGF receptor 2.

@ast

Potent neutralization of VEGF ...... ected against VEGF receptor 2.

@en

prefLabel

Potent neutralization of VEGF ...... ected against VEGF receptor 2.

@ast

Potent neutralization of VEGF ...... ected against VEGF receptor 2.

@en

P1433

Q33242744-7A680132-642B-4F93-8C2E-1E555B820D5E

P1476

Q33242744-2FAA7EE8-9BBE-4154-AEED-1277A2B52869

P2093

Q33242744-0C49CCB7-9FB9-4473-9F96-23B891ABA5E4

Q33242744-189FF0FF-E989-4B7F-9857-AE52AFDAECA3

Q33242744-4D7B70C9-D322-42BE-A018-B64789672D7D

Q33242744-5CCBBA85-FFE0-4ADF-9985-98B6DD60D6C1

Q33242744-78616AFC-BA04-4DAC-B3E1-118CB6164641

Q33242744-C59FB4DC-A836-47D2-8543-F6CF0E45AA4A

Q33242744-D9E5E0A4-1E85-49C2-842C-84A1AF9C11A4

Q33242744-E85F636F-97BD-4E02-890A-E8E2D97B020A

Q33242744-EB9C0E97-00A7-4EF3-984B-7888A5FB245E

P304

Q33242744-166653BF-107D-4942-A1A3-DE3C909DBDBF

P31

Q33242744-EDA3C658-FEB4-4243-A8F0-D62D3EA2905D

P356

Q33242744-99F8B218-9564-4043-BB64-55C63DC9417D

P407

Q33242744-CFADBF59-82D8-464A-85FA-BDE997E2BB67

P433

Q33242744-CBEFC16E-FB80-4C27-B1E8-8DCC29651912

P478

Q33242744-8F3C1A5E-1B51-453E-8254-2C68210A7669

P577

Q33242744-40EACF4C-CFAA-4560-B8D5-EBC560C31CBE

P698

Q33242744-6ECCDDD6-1354-4E48-89A6-D82B26B7C970

P921

Q33242744-16AEF310-9490-4552-811D-FF75E6EC0C2B

P356

J.BBRC.2006.04.119

P1433

Biochemical and Biophysical Research Communications

P1476

Potent neutralization of VEGF ...... ected against VEGF receptor 2.

@en

P2093

Dale L Ludwig

http://www.w3.org/2001/XMLSchema#string

Dan Lu

http://www.w3.org/2001/XMLSchema#string

Elizabeth Navarro

http://www.w3.org/2001/XMLSchema#string

Haifan Zhang

http://www.w3.org/2001/XMLSchema#string

Hua-Quan Miao

http://www.w3.org/2001/XMLSchema#string

Kun Hu

http://www.w3.org/2001/XMLSchema#string

Paul Balderes

http://www.w3.org/2001/XMLSchema#string

Xenia Jimenez

http://www.w3.org/2001/XMLSchema#string

Zhenping Zhu

http://www.w3.org/2001/XMLSchema#string

P304

438-445

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBRC.2006.04.119

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

345

http://www.w3.org/2001/XMLSchema#string

P577

2006-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16682007

http://www.w3.org/2001/XMLSchema#string

P921